Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:AKRX
CUSIP00972810
Phone847-279-6100
Debt
Debt-to-Equity Ratio1.01
Current Ratio4.64
Quick Ratio3.37
Price-To-Earnings
Trailing P/E Ratio11.12
Forward P/E Ratio59.79
P/E Growth2.81
Sales & Book Value
Annual Sales$841.04 million
Price / Sales2.49
Cash Flow$0.4919 per share
Price / Cash34.03
Book Value$6.65 per share
Price / Book2.52
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-24,550,000.00
Net Margins-12.22%
Return on Equity-9.63%
Return on Assets-4.20%
Miscellaneous
Employees2,308
Outstanding Shares125,260,000
Market Cap$2,243.39
Akorn (NASDAQ:AKRX) Frequently Asked Questions
What is Akorn's stock symbol?
Akorn trades on the NASDAQ under the ticker symbol "AKRX."
How were Akorn's earnings last quarter?
Akorn, Inc. (NASDAQ:AKRX) announced its quarterly earnings results on Thursday, August, 4th. The company reported $0.58 EPS for the quarter, topping analysts' consensus estimates of $0.55 by $0.03. The firm earned $280.70 million during the quarter, compared to analyst estimates of $272.99 million. Akorn had a negative net margin of 12.22% and a negative return on equity of 9.63%. Akorn's quarterly revenue was up 27.1% compared to the same quarter last year. View Akorn's Earnings History.
What price target have analysts set for AKRX?
6 analysts have issued twelve-month price objectives for Akorn's stock. Their forecasts range from $14.00 to $34.00. On average, they expect Akorn's share price to reach $28.20 in the next year. This suggests a possible upside of 68.5% from the stock's current price. View Analyst Ratings for Akorn.
What is the consensus analysts' recommendation for Akorn?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 6 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
Who are some of Akorn's key competitors?
Some companies that are related to Akorn include Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), United Therapeutics (UTHR), Loxo Oncology (LOXO), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Ligand Pharmaceuticals (LGND) and Taro Pharmaceutical Industries (TARO).
Who are Akorn's key executives?
Akorn's management team includes the folowing people:
- Mr. Rajat Rai, Chief Exec. Officer (Age 51)
- Mr. Duane A. Portwood, Exec. VP & CFO (Age 52)
- Dr. Bruce Kutinsky, Chief Operating Officer (Age 52)
- Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 53)
- Mr. Jonathan Kafer, Exec. VP of Sales & Marketing (Age 55)
Has Akorn been receiving favorable news coverage?
Press coverage about AKRX stock has been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akorn earned a news sentiment score of 0.07 on Accern's scale. They also assigned news headlines about the company an impact score of 45.68 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Akorn's major shareholders?
Akorn's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Havens Advisors LLC (0.19%). Company insiders that own Akorn stock include Brian Tambi, Bruce Kutinsky, John N Kapoor and Kenneth Abramowitz. View Institutional Ownership Trends for Akorn.
Which institutional investors are buying Akorn stock?
How do I buy shares of Akorn?
Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akorn's stock price today?
One share of AKRX stock can currently be purchased for approximately $16.74.
How big of a company is Akorn?
Akorn has a market capitalization of $2.24 billion and generates $841.04 million in revenue each year. Akorn employs 2,308 workers across the globe.
How can I contact Akorn?
Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]
MarketBeat Community Rating for Akorn (NASDAQ AKRX)
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
